Epoch 16 - Biotech Continues its Negative Trajectory

In Depth Analysis of the Abysmal Q1 Data

Hello Avatar!  Welcome to another week of biotech analysis.  Despite the lack of a positive catalyst of any sort, the public market has shown small signs of life this week (we are not buying it).   The same negative story persists for biotech as XBI continues to grind lower.  This week will feature an alternative view of the Q1 biotech data from our fri…